JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients

  • 0Department of Obstetrics and Gynecology, Stavanger University Hospital, Stavanger, Norway.
Frontiers in Immunology +

|

July 1, 2024

|

July 1, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High-grade serous ovarian carcinoma patients show distinct immune phenotypes at diagnosis. These immune profiles may guide treatment selection and improve prognosis for ovarian cancer.

Area Of Science

  • Gynecologic Oncology
  • Immunology
  • Biomarker Discovery

Background

  • High-grade serous ovarian carcinoma (HGSOC) has a poor prognosis despite treatment advances.
  • Cytoreductive surgery is crucial for survival, necessitating tools to predict treatment response.
  • Serum cytokine profiling offers insights into immune status but is underutilized in HGSOC treatment.

Purpose Of The Study

  • To characterize pre-treatment and during-treatment immune responses in HGSOC patients.
  • To identify serum cytokine biomarkers for treatment stratification and prognosis.
  • To explore the relationship between immune phenotypes, surgical scoring, and treatment outcomes.

Main Methods

  • Longitudinal serum samples from 22 HGSOC patients were collected from diagnosis to response evaluation.
  • Patients were assigned to primary cytoreductive surgery or neoadjuvant chemotherapy (NACT).
  • Serum cytokines were analyzed using Bio-Plex 200 to define immune phenotypes (Immune High vs. Immune Low).

Main Results

  • Two distinct immune phenotypes (Immune High and Immune Low) were identified at diagnosis, correlating with laparoscopy scores and treatment allocation.
  • Immune High patients undergoing cytoreductive surgery showed better progression-free survival than Immune Low patients.
  • Surgery induced transient cytokine changes (e.g., IL-6 upregulation, IP-10, Eotaxin, IL-4, IL-7 downregulation), with levels decreasing over time.

Conclusions

  • Distinct pre-treatment immune phenotypes in HGSOC patients can inform treatment stratification and prognosis.
  • Serum cytokine profiling shows potential as a novel biomarker for assessing treatment response in ovarian cancer.
  • Further validation of these immune phenotypes may enhance personalized treatment strategies for HGSOC.

Keywords: